Free Trial
→ Did you grab your copy yet? (From Profits Run) (Ad)tc pixel
NASDAQ:CLDX

Celldex Therapeutics Q3 2026 Earnings Date & Estimates

Celldex Therapeutics logo
$28.25 -1.18 (-4.01%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$28.25 0.00 (0.00%)
As of 10/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celldex Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for November 2, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Celldex Therapeutics in Q3 2026

Celldex Therapeutics is expected to post earnings of -$1.02 per share on revenue of $0.72 million. In the same quarter a year earlier Celldex Therapeutics reported -$1.01 per share. Celldex Therapeutics last reported on August 6, 2026, posting -$0.94 per share and beating the -$1.06 consensus estimate. Celldex Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.02
Expected Revenue
$0.72 million
Prior-Year EPS
-$1.01

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.94 (Beat by +$0.12)
Last Quarter Revenue
$0.02 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Celldex Therapeutics Q3 2026 Earnings FAQ

Celldex Therapeutics (NASDAQ:CLDX) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Celldex Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Celldex Therapeutics to post earnings of -$1.02 per share for Q3 2026.

The consensus revenue estimate for Celldex Therapeutics is $0.72 million for Q3 2026.

Celldex Therapeutics Earnings Headlines

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
October 12 at 9:10 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-celldex-therapeutics-inc-nasdaq-cldx-302905157.html
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Has Consensus Price Target of $61.92
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101614
Did you grab your copy yet?
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.tc pixel
 |  Profits Run (Ad)
Celldex Therapeutics: Trying To Put Its Troubled History Behind It
October 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952398-celldex-therapeutics-trying-to-put-its-troubled-history-behind-it?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) vs. Senti Biosciences (NASDAQ:SNTI) Critical Survey
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095560
Celldex (CLDX) Receives a Rating Update from a Top Analyst
October 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4951405/celldex-cldx-receives-a-rating-update-from-a-top-analyst/
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells. The company is evaluating barzolvolimab in conditions including chronic spontaneous urticaria and prurigo nodularis. Celldex also maintains an oncology and immunology pipeline that includes investigational antibody programs designed to stimulate or regulate immune responses.

Founded in the United States, Celldex conducts research and clinical development activities through collaborations and clinical studies in the U.S. and other international markets. The company is headquartered in Hampton, New Jersey, and is led by Anthony S. Marucci, who serves as president and chief executive officer.

View Celldex Therapeutics Profile
Earnings Tools